Disease relevance
KritRNA begins with selected nonsense-mutation contexts in HBB, DMD and CFTR, including an India-priority focus on β-thalassemia.
India-first
Built in India.
Designed for global science.
KritRNA is being developed by Transloka Bio Pvt. Ltd. in Noida as an India-first suppressor-tRNA platform. India-first does not mean India-only: it means building scientific ownership, evidence generation and disease priorities from India while meeting globally credible standards.
10 — the India-first proposition
Start where the need, science and execution can meet
The company is not using India as a marketing label. The proposition is to build a defensible biotechnology platform, validation network and future development pathway from the Indian research ecosystem.
Scientific ownership
The computational platform, candidate logic and future experimental evidence are being organised as company-owned capability developed from India.
Validation network
The development path depends on Indian CROs, research laboratories, clinicians, hospitals and rare-disease communities working through formal collaborations.
Access-aware development
Early decisions about indication, assay, delivery and evidence should reflect the realities of patients, healthcare systems and research infrastructure in India.
Initial focus
Three programs with different biological and access questions
HBB, DMD and CFTR provide distinct tests of the same platform thesis. Each program requires its own mutation context, amino-acid restoration logic, assay system, delivery strategy and safety evidence.
These are early research programs. KritRNA does not currently offer a treatment, clinical trial or patient-enrolment pathway.
Execution pathway
Evidence before expansion
The India-first strategy is organised around an evidence sequence rather than broad claims of platform readiness.
Define locally relevant mutation contexts
Select disease and variant contexts where the biology, unmet need and experimental path can be defended.
Design candidates computationally
Generate and rank suppressor-tRNA candidates using the KritRNA platform and documented biological constraints.
Validate through formal collaborations
Test selected candidates through appropriate research laboratories, CROs and disease-relevant experimental systems.
Build evidence before expansion
Advance only when reproducible molecular, protein-restoration and safety evidence supports the next step.
India-first scientific infrastructure requires collaborators.
KritRNA is open to structured discussions with research laboratories, CROs, clinicians, hospitals, incubators, grant programmes, patient organisations and aligned investors.